EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Advancing biopharmaceutical manufacturing: economic and sustainability assessment of end-to-end continuous production of monoclonal antibodies

Behnam Partopour, David Pollard

Trends in Biotechnology · 2025-02 · 43 (2) · 462-475

DOI: 10.1016/j.tibtech.2024.10.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Biotechnology, 2025-02. Verfasst von Behnam Partopour und 1 weiteren Autor:innen. Beteiligte Einrichtung: Corporate Research, Sartorius, Marlborough, MA, USA. Electronic address: Behnam.partopour@sartorius.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Biotechnology. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies (mAbs) have become essential therapeutics for treating various diseases. The robust, cost-effective, and sustainable production of mAbs is crucial due to their growing clinical and commercial demand. Advances in bioprocessing, such as improved cell lines, perfusion bioreactors, multicolumn chromatography, and automation, can significantly increase productivity, making treatments more accessible. Streamlining the production process also aligns with environmental sustainability by reducing waste and energy consumption. This study quantifies the economic and environmental impacts of incorporating recent advances into end-to-end continuous bioprocessing of mAbs. The results demonstrate that, compared with an optimized best-in-class fed-batch process (with 15 g/l titer and multicolumn chromatography), continuous manufacturing can reduce the total annual production costs, facility footprint, plastic waste, and CO2 emissions by up to 23%, 51%, 57%, and 54%, respectively, in a multiproduct facility producing clinical and commercial lots. Additionally, uncertainty analysis indicates that these gains are even more substantial under demand fluctuations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalBiotechnologyBioreactorsHumansAnimalsBatch Cell Culture TechniquesCricetulus

Stichwörter der Autor:innen

biomanufacturingcontinuous processingmonoclonal antibodiesprocess economicsprocess intensificationsustainability

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Corporate Research, Sartorius, Marlborough, MA, USA. Electronic address: Behnam.partopour@sartorius.com.
  • Corporate Research, Sartorius, Marlborough, MA, USA.

Zitieren

APA

Partopour, B., & Pollard, D. (2025). Advancing biopharmaceutical manufacturing: economic and sustainability assessment of end-to-end continuous production of monoclonal antibodies. Trends in Biotechnology, 43(2), 462-475. https://doi.org/10.1016/j.tibtech.2024.10.007

Vancouver

Partopour B, Pollard D. Advancing biopharmaceutical manufacturing: economic and sustainability assessment of end-to-end continuous production of monoclonal antibodies. Trends in Biotechnology. 2025;43(2):462-475. doi:10.1016/j.tibtech.2024.10.007

BibTeX
@article{Partopour2025,
  author = {Partopour, Behnam and Pollard, David},
  title = {Advancing biopharmaceutical manufacturing: economic and sustainability assessment of end-to-end continuous production of monoclonal antibodies},
  journal = {Trends in Biotechnology},
  year = {2025},
  volume = {43},
  number = {2},
  pages = {462--475},
  doi = {10.1016/j.tibtech.2024.10.007}
}
Kostenlos starten →